Cipla diclofenac sodium gel recalled for failed pH specifications
Cipla USA is recalling Diclofenac Sodium Topical Gel 1% (batch XHBG, expiring 08/31/2027) because it failed to meet required pH specifications during quality testing. The gel may not work as intended or could cause skin irritation. No injuries have been reported so far.
From the FDA notice · Read the official notice ↗ · All Cipla recalls
What to do
- Stop using this gel if you have batch XHBG with expiration date 08/31/2027
- Check the batch number on your tube
- Contact your pharmacy or doctor for a replacement or alternative pain relief option
- Return unused gel to your pharmacy
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Units affected
- 92,376 tubes
- Illnesses reported
- None reported
- Manufactured in
- 10 Independence Blvd, Warren, NJ, United States
- Classification
- Class III
- Recall number
- D-0291-2026
In the FDA's words
- Description
- Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: DPT Laboratories, Ltd., 307 E Josephine Street, San Antonio, TX 78215. NDC: 76282-103-39 Failed PH Specifications Batch XHBG; Exp. 08/31/2027 Distribution: Nationwide in the USA Affected quantity: 92,376 tubes
- Hazard
- Failed PH Specifications
More from Cipla
See all- Cipla USA fosfomycin granules recalled for failed impurity specs
ModerateFDAOct 14, 2026